Crystalline potassium salt of lipoxin A4 analogs
View Patent ↗This invention is directed to the crystalline potassium salt of a lipoxin A 4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.
1. A crystalline potassium salt of 2-((2S,3R,4E,6E,10E,12S)-13-(4-fluorophenoxy)-2,3,12-trihydroxytrideca-4,6,10-trien-8-ynyloxy)acetate:
which is
in the form of an anhydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=26.7 Å;
in the form of an anhydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=26.7 Å and about d=3.7 Å;
in the form of a monohydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=26.5 Å;
is in the form of a monohydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=26.5 Å, about d=4.3 Å and about d=4.0 Å;
in the form of a dihydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=27.1 Å; or
in the form of a dihydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=27.1 Å, about d=4.2 Å and about d=4.1 Å.
2. The crystalline potassium salt according to claim 1 wherein the crystalline potassium salt is in the form of an anhydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=26.7 Å.
3. The crystalline potassium salt according to claim 1 wherein the crystalline potassium salt is in the form of an anhydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=26.7 Å and about d=3.7 Å.
4. The crystalline potassium salt according to claim 1 wherein the crystalline potassium salt is in the form of a monohydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=26.5 Å.
5. The crystalline potassium salt according to claim 1 wherein the crystalline potassium salt is in the form of a monohydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=26.5 Å, about d=4.3 Å and about d=4.0 Å.
6. The crystalline potassium salt according to claim 1 wherein the crystalline potassium salt is in the form of a dihydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=27.1 Å.
7. The crystalline potassium salt according to claim 1 wherein the crystalline potassium salt is in the form of a dihydrate characterized by a X-ray powder diffraction pattern having a characteristic peak at about d=27.1 Å, about d=4.2 Å and about d=4.1 Å.
8. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a therapeutically effective amount of a crystalline potassium salt of claim 1 .
9. The crystalline potassium salt according to claim 1 , wherein the crystalline potassium salt has the X-ray powder diffraction patterns illustrated in FIG. 2 and is a monohydrate.
10. The crystalline potassium salt according to claim 1 , wherein the crystalline potassium salt has the X-ray powder diffraction patterns illustrated in FIG. 2 and is a dihydrate.